Abstract
We report two cases of hyperkalaemia related to the use of the salt substitute ‘Lo Salt’ in hypertensive patients on treatment with ACE inhibitors. In each case serum potassium returned to the normal range after cessation of the salt substitute. Without vigilance the contribution of the salt substitute to hyperkalaemia would have been overlooked and an ACE inhibitor erroneously withdrawn.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ray, K., Dorman, S. & Watson, R. Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction. J Hum Hypertens 13, 717–720 (1999). https://doi.org/10.1038/sj.jhh.1000890
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000890
- Springer Nature Limited
Keywords
This article is cited by
-
The hypotensive effect of salt substitutes in stage 2 hypertension: a systematic review and meta-analysis
BMC Cardiovascular Disorders (2020)
-
Review of case reports on hyperkalemia induced by dietary intake: not restricted to chronic kidney disease patients
European Journal of Clinical Nutrition (2019)
-
Evaluation of community pharmacists’ knowledge and awareness of food–drug interactions in Palestine
International Journal of Clinical Pharmacy (2018)
-
Treatment of Hyperkalemia in Heart Failure
Current Heart Failure Reports (2017)
-
Drug-Induced Hyperkalemia
Drug Safety (2014)